| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MLC-2a; MLC2a; MLRA; MYL7; MYLC2A |
| Entrez GeneID | 10627; |
| WB Predicted band size | 18kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Peptide sequence around phosphorylation site of serine 19 (A-T-S(p)-N-V) derived from Human Myosin Light Chain 2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Myosin Light Chain 2 (Phospho-Ser19)抗体的参考文献示例(文献标题和内容为虚构，仅供格式参考)：
---
1. **"Rho kinase regulates phosphorylation of myosin light chain 2 in vascular smooth muscle contraction"**
*作者：Somlyo AP, et al.*
摘要：研究通过Western blot和免疫荧光技术，利用Phospho-Ser19抗体证明Rho激酶通过直接磷酸化MLC2的Ser19位点调控血管平滑肌收缩，并揭示其在高血压病理中的作用。
2. **"Calcium sensitization mechanisms in airway smooth muscle: Role of MLC2 phosphorylation"**
*作者：Janssen LJ, et al.*
摘要：该文献使用Phospho-Ser19特异性抗体，证实钙离子信号通过激活MLCP(肌球蛋白轻链磷酸酶)抑制通路，增强MLC2 Ser19磷酸化水平，从而加剧哮喘模型中的气道高反应性。
3. **"Phosphorylation-dependent targeting of myosin light chain 2 in endothelial barrier dysfunction"**
*作者：Garcia JG, et al.*
摘要：通过免疫沉淀和Phospho-Ser19抗体检测，发现炎症因子(如TNF-α)诱导的MLC2磷酸化破坏内皮细胞连接，为急性肺损伤提供分子机制证据。
4. **"A novel ROCK inhibitor attenuates MLC2 phosphorylation in cardiac hypertrophy"**
*作者：Shimokawa H, et al.*
摘要：研究利用Phospho-Ser19抗体评估新型ROCK抑制剂对心肌肥厚模型中MLC2磷酸化的抑制作用，提示其治疗心力衰竭的潜力。
---
注：以上文献为示例，实际引用需根据具体研究通过PubMed或学术数据库检索。建议使用关键词 **"myosin light chain 2 Ser19 phosphorylation antibody"** 或结合 **"smooth muscle contraction"**、**"ROCK signaling"** 等主题筛选近期论文。
The Myosin Light Chain 2 (MLC2) Phospho-Ser19 antibody detects the phosphorylated form of myosin regulatory light chain 2 (MLC2) at serine residue 19. a post-translational modification critical for regulating smooth muscle and non-muscle cell contractility. MLC2. a component of myosin II, plays a key role in actomyosin contractility by modulating myosin ATPase activity. Phosphorylation at Ser19. mediated by myosin light chain kinase (MLCK) or Rho-associated kinase (ROCK), induces conformational changes in myosin II, enabling actin filament crosslinking and force generation. This process is essential for physiological functions such as smooth muscle contraction, cell migration, cytokinesis, and vascular tone regulation.
The antibody specifically recognizes the phosphorylated Ser19 epitope, allowing researchers to study MLC2 activation status in cellular pathways involving cytoskeletal dynamics, mechanotransduction, or stress fiber formation. It is widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate conditions linked to aberrant contractility, including hypertension, asthma, cancer metastasis, and neurological disorders. Detection of phosphorylated MLC2 (Ser19) also serves as a biomarker for Rho/ROCK or calcium/calmodulin signaling activity, providing insights into drug targeting or disease mechanisms. Proper controls (e.g., phosphatase-treated samples) are recommended to confirm antibody specificity.
×
